04/12/2025
Practice
Clinical Updates
Assessment and management of albuminuria in adults
BMJ 2025; 391 doi: https://doi.org/10.1136/bmj-2025-084911 (Published 25 November 2025)
Cite this as: BMJ 2025;391:e084911
What you need to know
Regular testing (at least annually) for albuminuria with urine albumin-creatine ration (UACR) is recommended for risk stratification in patients with or at risk for chronic kidney disease (CKD), including those with diabetes, hypertension, and/or cardiovascular disease
In epidemiological studies, a >30% reduction in albuminuria was associated with up to 56% lower risk of kidney failure and 28% lower risk of cardiovascular disease
Antiproteinuric therapies are recommended for treatment of CKD by clinical guidelines including KDIGO. Consider angiotensin receptor blockers, angiotensin converting enzyme inhibitors, sodium glucose co-transporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, or glucagon-like peptide receptor agonists, depending on the clinical situation
Consider referral to nephrology for albuminuria when there is concern for glomerulonephritis, the cause of albuminuria is unknown, risk prediction tools suggest the 5 year risk of kidney failure is >3-5%, urine albumin-to-creatinine ratio (UACR) >30 mg/mmol; UACR >3 mg/mmol with additional risk factors, or there is severe albuminuria with haematuria
This website is using a security service to protect itself from online attacks. The action you just performed triggered the security solution. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data.